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Supplying Pharmacist Home Visit and Anticoagulation
Professional Consultation During Transition of Care for
Patients With Venous Thromboembolism
Alok Kapoor, MD, MSc,*†‡ Valentina Landyn, BS,‡ Joann Wagner, MSW,‡ Pamela Burgwinkle, MS, APN,*
Wei Huang, PhD,† Joel Gore, MD,*† Frederick A. Spencer, MD,§ Robert Goldberg, PhD,†
David D. McManus, MD, ScM,*†‡ Chad Darling, MD, MSc,*† Edwin Boudreaux, PhD,†
Bruce Barton, PhD,† and Kathleen M. Mazor, EdD†‡
Objective: The aim of the study was to assess the feasibility, satisfaction,
and effectiveness of a care transition intervention with pharmacist home
visit and subsequent anticoagulation expert consultation for patients with
new episode of venous thromboembolism within a not-for-profit health
care network.
Methods: We randomized patients to the intervention or control. During
the home visit, a clinical pharmacist assessed medication management
proficiency, asked open-ended questions to discuss knowledge gaps, and
distributed illustrated medication instructions. Subsequent consultation
with anticoagulation expert further filled knowledge gaps. At 30 days,
we assessed satisfaction with the intervention and also measured the quality
of care transition, knowledge of anticoagulation and venous thromboem-
bolism, and anticoagulant beliefs (level of agreement that anticoagulant
is beneficial, is worrisome, and is confusing/difficult to take).
Results: The mean ± SD time required to conduct home visits was
52.4 ± 20.5 minutes and most patients agreed that the intervention was
helpful. In general, patients reported a high-quality care transition includ-
ing having been advised of safety issues related to medications. Despite
that, the mean percentage of knowledge items answered correctly among
patients was low (51.5 versus 50.7 for intervention and controls, re-
spectively). We did not find any significant difference between inter-
vention and control patients for care transition quality, knowledge, or
anticoagulant beliefs.
Conclusions: We executed a multicomponent intervention that was
feasible and rated highly. Nevertheless, the intervention did not improve
care transition quality, knowledge, or beliefs. Future research should exam-
ine whether alternate strategies potentially including some but not all com-
ponents of our intervention would be more impactful.
Key Words: venous thromboembolism, anticoagulation, care transitions,
clinical pharmacology, medication safety, patient education
(J Patient Saf 2020;16: e367–e375)
T he National Action Plan for Adverse Drug Event Preventionidentified anticoagulants as the drug class most associated
with patient safety incidents in the U.S.1 This is particularly
concerning for patients with venous thromboembolism (VTE),
including deep vein thrombosis (DVT) and pulmonary embolism
(PE). Unlike patients with atrial fibrillation or other cardiac in-
dications for anticoagulation who routinely receive follow-up
with a cardiologist, patients with VTE may not receive any fol-
low-up with a physician specialist. Moreover, although antico-
agulation clinics are available in some health systems, they
primarily serve patients prescribed warfarin and not direct oral
anticoagulants (DOACs).2
The lack of timely, specialized guidance for many patients with
new episodes of VTE can contribute to adverse clinical endpoints.
Several studies have documented that the rate of recurrent VTE and
major bleeding are highest in the first month after diagnosis.3–5 This
period includes the time of care transition, defined as “movement of
patients between health care practitioners, settings, and home as
their condition and care needs change.”6 Researchers have begun
to measure the quality of care transitions.7 High-quality care
transitions include thorough transmission of information to
patients, organization of appointments, and empowerment of
the patient to care for himself or herself. Although there is
limited research establishing the linkage between improving
the quality of care transition and lowering the rate of recurrent
VTE and bleeding events, there are related examples where im-
proving patient knowledge and adherence has led to fewer of these
adverse events.8–13
Direct assessment of patient medicationmanagement, such as a
pharmacist home visit shortly after discharge, is one potential
strategy for improving the quality of care transition, patient knowl-
edge, and adherence. Previous studies14,15 demonstrated a benefit
to pharmacist home visits in terms of identifying drug-related
problems and improving adherence. However, these home visit
studies occurred outside of the U.S. and were not focused specif-
ically on patients with new episodes of VTE. Given the complex-
ities of U.S. healthcare, retesting the value of a home pharmacist
visit in patients shortly after diagnosis of VTE in the U.S. would
be an important contribution to scientific knowledge.
From the *University of Massachusetts Memorial Health Care; †University of
Massachusetts Medical School; ‡Meyers Primary Care Institute, a joint
endeavor of University of Massachusetts Medical School, Reliant Medical
Group, and Fallon Health, Worcester, MA; and §McMaster University,
Hamilton, Ontario, Canada.
Correspondence: Alok Kapoor, MD, Meyers Primary Care Institute,
365 Plantation St, Worcester, MA 01605
(e‐mail: Alok.Kapoor@umassmemorial.org).
The authors disclose no conflict of interest.
This study was supported by Pfizer through its Independent Grants for Learning
and Change Initiative and National Center for Advancing Translational
Sciences of the National Institutes of Health under Award Number
UL1TR000161 for REDCap software development and dissemination. The
content is solely the responsibility of the authors and does not necessarily
represent the official views of the NIH.
This clinical study is registered with the U.S. National Library of Medicine
database at http://www.clinicaltrials.gov under the Registration
Number NCT02870296.
Supplemental digital contents are available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions
of this article on the journal’s Web site (www.journalpatientsafety.com).
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
This is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-
NC-ND), where it is permissible to download and share the work provided
it is properly cited. The work cannot be changed in any way or used
commercially without permission from the journal.
ORIGINAL ARTICLE
J Patient Saf • Volume 16, Number 4, December 2020 www.journalpatientsafety.com e367
Use of illustratedmedication instructions is another strategy for
improving the quality of care transition, patient knowledge, and
adherence. Medication instructions are not understandable or en-
gaging to the average patient.16 Moreover, whereas issuance of
medication instructions is standard with discharge from the hospi-
tal, patients who are diagnosed and started on treatment without a
visit to either a hospital or an emergency department may not re-
ceive any written instructions at all.17Well-written patient instruc-
tionswith illustrations can overcome the problems associated with
typical medication instructions.18
A third strategy to improving the quality of care transition,
patient knowledge, and adherence is adding a second point of
consultation a week after the home visit. Several published care
transition interventions included telephone calls early after dis-
charge (i.e., 1–5 days after discharge) without any subsequent
contact or education offered to patients.19–24 A second point of
contact, such as a telephone consultation with an expert, a week
or more after a home visit, may reinforce topics discussed in the
initial consultation.
We conducted a randomized controlled trial to assess the com-
bination of previous strategies, including a pharmacist home visit,
illustrated medication instructions, and subsequent telephone
consultation with an anticoagulation expert in patients diagnosed
with new episodes of VTE. To assess effectiveness, we measured
the quality of care transition, patient knowledge, and adherence
(through inquiring about patient anticoagulation beliefs). To
assess the feasibility of, and satisfaction with our intervention,




We identified adults 18 years and older diagnosed with a new
episode of VTE and prescribed anticoagulation. To be eligible,
we required confirmation of DVTor PE through radiologic exam.
In terms of anticoagulation, we included participants prescribed
warfarin, DOACs, or an injectable agent (low-molecular weight
heparin or fondaparinux). We excluded patients discharged to a
rehabilitation or skilled nursing facility, patients who did not
speak English, patients whowere unable to self-consent, pregnant
patients, and prisoners.
Setting
This study was conducted within the UMass Memorial
Health Care system, a multihospital health care system in central
Massachusetts. The University of Massachusetts Medical School
institutional review board reviewed and approved this study.
Procedure
Recruitment and Randomization
For patients approached in the hospital or emergency depart-
ment, we obtained written consent during our initial meeting.
We subsequently randomized these patients after their discharge.
In contrast, for patients recruited by telephone, we obtained verbal
consent and subsequently performed randomization the same day.
We then sought written consent via mail and made up eight
telephone calls to remind the patient to return the forms. If the
patient did not return the consent forms within 50 days of providing
verbal consent, we treated this patient as unenrolled and did not
report further data.
Randomization Protocol
We randomized study patients to either intervention or control,
stratified by anticoagulation type (warfarin, DOAC, or injectable).
Specifically, we adjusted block size for each strata based on previ-
ous data about the distribution of anticoagulation type within
our facility.
Baseline Interview
After obtaining consent, study staff conducted an interview to
collect demographic information, patient activation through the
13-item Patient Activation Measure,25 and depression through
two questions from the Patient Health Questionnaire.26 Our in-




To conduct home visits, we required our pharmacists to hold active
state registered pharmacist licensure through the Commonwealth of
Massachusetts.Our pharmacist team included five school of pharmacy
faculty members and three pharmacy residents. To ensure standardiza-
tion of the home visit, we composed a manual for the conduct of
home visits (Appendix A, http://links.lww.com/JPS/A212).29
Home Visit Protocol
For patients allocated to the intervention arm, we scheduled a
home visit with a clinical pharmacist to occur within 7 days of ran-
domization. Before the visit, we provided the pharmacist the most
current documentation available regarding the new VTE episode
(e.g., discharge summary, emergency department record, or outpa-
tient clinic note). We also supplied the pharmacist a list of medica-
tions, which was entered into an online software that generates
illustrated medications instructions, PictureRx (mypicturerx.com),
developed through National Institutes of Health funding and later
purchased and optimized by Bioscape Digital Inc (Atlanta, GA).30
The visit consisted of three parts. Initially, the pharmacist
conducted a medication self-management simulation that builds
on the “show me” paradigm advocated by experts.31 This followed
a protocol we previously validated.32
In the second part of the home visit, the clinical pharmacist
asked a series of open-ended questions to assess patient under-
standing of medications and VTE condition. These included
questions about lab work required for patients on warfarin, die-
tary issues while on an anticoagulant, medication interactions,
adverse reactions with anticoagulant, and symptoms to report
to the anticoagulation prescriber.
In the final part of the home visit, the pharmacist reviewed and
updated the list of medications in PictureRx. Instructions from
PictureRx included a picture of the anticoagulant medication, a
picture of the indication for the use of each medication, and a pic-
torial of the time of day when each medication should be taken
(see Appendix B for example, http://links.lww.com/JPS/
A213).19 The pharmacist printed a color copy of the illustrations
using a portable printer provided to the pharmacist for the study.
Togauge the feasibility of conducting the different parts of the home
visit, the pharmacists recorded the start and end times for individual
parts of the visit, as well as the total time they spent in the home.
Anticoagulation Expert Consultation
Subsequent to the home visit, the anticoagulation expert, a
nurse practitioner working in the UMass Memorial Health Care
Anticoagulation Clinic, contacted the patient via telephone. This
occurred from 8 to 30 days from study randomization. During the
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TABLE 1. Comparison of Key Characteristics Recorded at Beginning of Intervention for Patients From Three Provider Groups
Intervention Patients Control Patients
Characteristic Frequency (% of 77 Total) Frequency (% of 85 Total) P
Age, y
75+ 16 (20.8) 14 (16.5) 0.46
65–74 21 (27.3) 22 (25.9)
55–64 13 (16.9) 23 (27.1)
<55 27 (35.1) 26 (30.6)
Sex
Female 32 (41.6) 38 (44.7) 0.69
Male 45 (58.4) 47 (55.3)
Racial background
White 68 (88.3) 64 (75.2) 0.18
Black 4 (5.2) 7 (8.2)
Asian/Pacific Islander/Native American/Alaskan/More than one race 2 (2.6) 6 (7.1)
Don't know/prefer not to answer/missing 3 (3.9) 8 (9.4)
Ethnicity
Hispanic 2 (2.6) 9 (10.6) 0.09
Non-Hispanic 73 (94.8) 72 (84.7)
Don't know/prefer not to answer/missing 2 (2.6) 4 (1.2)
Income level
≤100% poverty level 8 (10.4) 5 (5.9) 0.30
100%–400% poverty level 19 (24.7) 15 (17.7)
>400% poverty level 23 (29.9) 24 (28.2)
Don't know/prefer not to answer/missing 27 (35.1) 41 (48.2)
Education
High school or below 21 (27.3) 18 (21.2) 0.54
Above high school 54 (70.1) 63 (74.1)
Missing 2 (2.6) 4 (4.7)
Health literacy – confidence filling out medical forms
Inadequate (somewhat/a little bit/not at all) 21 (27.3) 17 (20.0) 0.46
Adequate (extremely/quite a bit) 54 (70.1) 64 (75.3)
Missing (don't know/prefer not to answer) 2 (2.6) 4 (4.7)
Health literacy – hard time understanding when people speak quickly?
Strongly agree or agree 36 (48.0) 36 (43.9) 0.83
Disagree or strongly disagree 39 (52.0) 46 (56.1)
Missing 3 (2.6) 2 (4.7)
Patient activation – PAM-13 score
1 – Disengaged and overwhelmed 4 (5.2) 8 (9.4) 0.44
2 – Becoming aware, but still struggling 11 (14.5) 18 (21.2)
3 – Taking action 31 (40.8) 28 (32.9)
4 – Maintaining behaviors and pushing further 30 (39.5) 31 (36.5)
Charlson Comorbidity Index
0 35 (21.6) 29 (17.9) 0.03
1 21 (13.0) 17 (10.5)
2 8 (4.9) 23 (14.2)
3+ 13 (8.0) 16 (9.9)
VTE type
DVT alone 40 (52.0) 33 (38.8) 0.25
PE 24 (31.2) 34 (40.0)
Both 13 (16.9) 18 (21.2)
(Continued next page)
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consultation, patients were asked the same series of open-ended
questions posed during the home visit. The nurse practitioner re-
viewed the patient's medication list, updated the list in PictureRx,
and mailed a color copy of the updated instructions to the patient.
Interaction With Primary Care Provider
If the pharmacist home visit or subsequent consultation identi-
fied a significant concern in terms of patient safety, the pharmacist
or nurse practitioner corresponded through secure e-mail with the
patient's primary care provider. For urgent matters, they called the
primary care provider to discuss the matter.
Control Patients
We informed control patients of their treatment allocation but did
not provide any education beyondwhat patients typically received. At
discharge from the hospital, a clinical pharmacist typically met with
each patient prescribed anticoagulation. We did not provide a pro-
tocol or curriculum to conduct these encounters. Nomedication sim-
ulations or illustrated medication instructions were provided during
the study. In addition, patients discharged from the emergency de-
partment or other outpatient setting did not typically meet with a
clinical pharmacist.
Follow-Up Interview
We asked all patients to complete a follow-up telephone inter-
view 30 to 50 days after randomization. During that interview,
we collected information that formed the basis of the outcomes
we measured (see outcomes section). Patients who completed
the follow-up interview received a U.S. $25 gift card.
Outcomes
Feasibility and Satisfaction
We calculated the mean time required for conducting each por-
tion of the home visit and the anticoagulation expert consultation.
We also asked patients to report their level of agreement with
statements about the helpfulness of each of the individual parts
of the intervention using a five-item Likert response format rang-
ing from strongly agree to strongly disagree.
Effectiveness
(1) Quality of care transition. We measured quality of the care
transition using the Care TransitionMeasure (CTM) 15 developed
and validated previously by Coleman et al.7 (Appendix C, http://
links.lww.com/JPS/A214). After gathering responses from each
patient, we calculated a global score on a scale of 0 to 100, follow-
ing an algorithm published by the developer of the instrument.33
(2) Knowledge. We also assessed patient knowledge regarding
anticoagulation and the interactions, risks, and signs and symptoms
to report to the anticoagulation prescriber. Specifically, we adminis-
tered a modified version of a previously published questionnaire28
(Appendix D, http://links.lww.com/JPS/A215). We calculated a
total score as a percentage of items answered correctly.
(3) Anticoagulant Beliefs. Previous studies have demonstrated
that a patient's beliefs about a medication predict his or her ad-
herence to it.34We therefore administered a previously published
questionnaire,28 which included 14 items assessing a patient's be-
liefs about the anticoagulant prescribed to him or her (Appendix
E, http://links.lww.com/JPS/A216). Four of these items comprised
a subsidiary outcome “Anticoagulant is Beneficial.” They assessed
the extent to which a patient believed that his current and future
health depended on his anticoagulant and whether he would be-
come ill without his anticoagulant. Five questions assessed worry
about health and adverse effects since starting an anticoagulant.
Finally, five questions assessed patient confusion and difficulty
with taking an anticoagulant. All items used a response scale
ranging from 1 to 5, with corresponding response options ranging
from strongly disagree to strongly agree.
Covariates
We adjusted our outcomes for age, sex, race, ethnicity, poverty
level, educational attainment, health literacy, patient activation,
VTE type, anticoagulant prescribed, etiologyofVTE event, Charlson
score, and setting of care transition in categories as listed in Table 1.
TABLE 1. (Continued)
Intervention Patients Control Patients
Characteristic Frequency (% of 77 Total) Frequency (% of 85 Total) P
VTE etiology
Provoked VTE 28 (36.4) 35 (41.2) 0.92
Cancer associated 9 (11.7) 10 (11.8)
Unprovoked VTE 31 (40.3) 30 (35.3)
Unclear/unable to determine/missing 9 (11.7) 10 (11.8)
VTE history
Yes 27 (35.1) 24 (28.2)
No 49 (63.6) 58 (68.2) 0.40
Unclear/unable to determine/missing 1 (1.3) 3 (3.5)
Anticoagulant prescribed
Warfarin 37 (48.1) 39 (45.9) 0.92
Novel oral anticoagulant 29 (37.7) 32 (37.7)
Enoxaparin 11 (14.3) 14 (16.5)
Care transition type
Hospital to home 48 (62.3) 59 (69.4) 0.49
Emergency department to home 15 (19.5) 16 (18.8)
Ambulatory to home 14 (18.2) 10 (11.8)
PAM-13, Patient Activation Measure-13; VTE, venous thromboembolism.
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Analysis
First, we calculated the distribution of the covariates mentioned
previously for intervention versus control patients. We then com-
pared outcomes for these patients first in an unadjusted fashion.
We then controlled for covariates using multiple linear regressions
to account for residual confounding and loss to follow-up of
patients after randomization. We also examined the effect of our
intervention in key subsets of patients including a subset restricted
to patients transitioning from hospital to home and a subset restricted
to those patients for whom the VTE event was unprovoked and
not related to cancer.
RESULTS
Of the 415 eligible patients, 194 verbally consented to participate
in the study and were still eligible at the time of randomization.
Because we required written consent, and many patients did not
return written consent documents to us, our final fully consented
cohort included 163 patients. These 163 patients participated in
30-day interviews from which we derive our outcome results.
From these 163 intention-to-treat cohort, 49 patients received both
the home visit and consultation from the anticoagulation expert.
Together with the 77 patients in the control group, our completers
cohort included 126 patients (Fig. 1; Table 1).
Feasibility and Satisfaction Results
The mean ± SD time from consent to home visit was 5.4 ±
2.1 days. The mean ± SD time required to conduct home visits
was 52.3 ± 20.5minutes. Patients rated all parts of the intervention
highly with mean scores of nearly 4 or higher than 4 of 5, consis-
tent with agreement that the intervention was helpful (Table 2).
FIGURE 1. Study flow. *Fully Consented represent those individuals consented in person and providing written consent from the outset
and those consented by telephone and having returned written consent within 50 days of randomization.
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Fully Consented Cohort Descriptive Information
Among patients from the fully consented cohort, we found that
there was balance between intervention and control patients with
respect to most variables listed in Table 1. The age of our cohort
divided relatively evenly between the following age groups:
younger than 55, 55 to 64, 65 to 74, and 75 years or older. We
had slightly more men in our study. Most patients were white.
More than 70% of our sample had more than a high school educa-
tion. Most patients scored high in patient activation. The interven-
tion group had more patients in a lower Charlson Comorbidity
Index category compared with controls (P = 0.03).
Intention-to-Treat Cohort Results
In terms of outcomes, in general, we did not find a signifi-
cant difference between intervention and control patients. Most
patients rated the quality of their care transition highly. More
specifically, intervention patient mean ± SD score was 74.5 ± 12.6
versus 73.5 ± 19.6 for controls (Wilcoxon Kruskal Wallis P value
of 0.77). In both the intervention and control groups, more than
80% of patients agreed or strongly agreed that since receiving their
VTE diagnosis, they clearly understood the purpose of taking
each of their medications, including how much medicine to take
and when.
The mean ± SD percentage of knowledge items answered cor-
rectly among patients was low in both groups: 51.5 ± 11.2 versus
50.7 ± 13.2 for intervention and controls, respectively (Wilcoxon
Kruskal Wallis P value of 0.48). This was true even for patients
with graduate or higher-level education. Specific items that both
groups had a low level of knowledge included knowing that con-
suming beer or hard liquor could be a problem when taking anti-
coagulant medication. Less than 50% of patients answered these
items correctly. Less than 60% of patients understood that taking
an anticoagulant could cause their stomach to bleed (Table 3 for
full details).
We did not find any difference between groups in the anticoag-
ulant belief items apart from the item “taking my anticoagulation
as prescribed is easy” (Table 4).
Our multivariate analyses and subset analyses did not reveal
any significant differences in outcomes compared with the main
results reported previously.
Completers Cohort Results
Compared with controls, the subset of completers had a higher
percentage of white participants (95.9% versus 77.9%). Therewas
also a trend toward more patients in this cohort having DVTalone
(57.1% versus 42.9%) and making a transition from ambulatory
care setting to home (22.5% versus 13.0%) (See Appendix F for
full comparison, http://links.lww.com/JPS/A217)
Compared with the 77 controls, the 49 patients completing the
intervention in full did not report significantly better quality of
TABLE 2. Timing of Study Components and Satisfaction
Intervention Component Mean ± SD Time, min* Mean ± SD Satisfaction (Likert Scale)
Home visit (n = 65)
Simulation 23.8 ± 14.6
Open-ended 21.3 ± 13.0
Picture Rx 14.4 ± 11.0 3.9 ± 0.9†
Total 52.4 ± 20.5 4.6 ± 0.7‡
Anticoagulation expert consultation (n = 57)
Open-ended 7.8 ± 2.9
Picture Rx 2.8 ± 2.7 3.9 ± 0.9†
Total 10.4 ± 4.0 4.2 ± 0.7§
*Of the 65 completing home visits, we had total time recorded for all patients; similarly for the 57 patients having expert consultation, we had total time
for all of these patients; later in the study, we began collecting information about timing for the individual components and thus the number of patients for
whomwe had home visit timing of simulation, open-ended questions, PictureRx, expert consultation open-ended question, and repeat PictureRx was 64, 35,
45, 56, and 56, respectively.
†This reports “do you agree illustrated medication guide was helpful” on scale of 1–5 with 1 being strongly disagree and 5 being strongly agree; only
26 patients reported this information. This applies to the PictureRx29 intervention from both home and clinic visits.
‡This reports “doyou agree home visit was helpful” on scale of 1–5 with 1 being strongly disagree and 5 being strongly agree; of the 64 completing home
visits, only 53 patients reported this information.
§This reports “do you agree clinic visit was helpful” on scale of 1–5 with 1 being strongly disagree and 5 being strongly agree; only 49 patients reported
this information.
TABLE 3. Comparison of Intervention Versus Control Patients for Quality of Care Transition and Knowledge in the
Intention-to-Treat Cohort
Intervention Control P
Quality of Care Transition – CTM-157 (0–100 scale with higher number indicating higher quality) 74.5 ± 12.6 73.5 ± 19.6 0.77*
Knowledge (% correct on 22 item anticoagulant questionnaire27) 51.5 ± 11.2 50.7 ± 13.2 0.48*
*Based on Wilcoxon Kruskal-Wallis P value.
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care transition, higher knowledge, or higher adherence based on
response to believe questions.
DISCUSSION
We studied the impact of a multicomponent intervention
that included a pharmacist home visit with illustrated medica-
tion instructions and subsequent consultation with an antico-
agulation expert. The mean time required in the home was
feasible (i.e., similar to initial visits with other clinicians)
and patients rated these visits and the illustrated medication
instructions highly. Nevertheless, we did not find a benefit
in terms of overall quality of care transition, knowledge, or
anticoagulant beliefs.
Comparison with other studies in the literature is limited by dif-
ferences in the population examined and the outcomes assessed.
In a systematic review, Mekonnen et al.23 studied the impact of
medication reconciliation performed by a pharmacist. They found
that medication reconciliation led to large reductions in utilization
of hospital and ED after initial admission to the hospital for a va-
riety of conditions. By contrast, we focused on a single condition
and on outcomes related to the quality of care transition, knowl-
edge, and anticoagulant beliefs. We have not identified another
study that measured the same outcomes in patients newly diag-
nosed with VTE. A previous study conducted by members of
our authorship team (KM, JG, PB, JW) from which we borrowed
the knowledge instrument did demonstrate that anticoagulation
knowledge increased after a video intervention.28 In that study,
the authors included patients with all indications for warfarin, in-
dependent of the timing of medication initiation. The timing of
assessment of knowledge also differed between studies. They
assessed knowledge contemporaneously with distribution of the
video (i.e., a questionnaire accompanied video in a common
mailer). By contrast, we assessed knowledge at least 23 days after
the home visit and typically 2 weeks after consultation with an an-
ticoagulation expert. Thus, it is possible that our intervention also
had a temporary increase in knowledge but that increase lessened
over time. Our second contact with patients conducted by an anti-
coagulation expert was conducted over the telephone and lasted
only 10 minutes on average. More sustained increases in knowl-
edge may require a more intensive second contact or multiple
shorter telephone encounters.
There were several limitations to this study. As mentioned
previously, we did not power our study to detect a change in
medication errors or the clinical endpoints of recurrent VTE
or hemorrhage. We hypothesized that a poor-quality care tran-
sition, knowledge gaps, and absence of belief could contribute
to the development of medication errors and subsequent adverse
clinical endpoints. Further research in a larger sample would
better assess the value of a pharmacist home visit and the other
components of our intervention on the development of errors,
recurrent VTE, and hemorrhage.
The nature of our recruitment strategy, which relied heavily on
verbal consent followed by subsequent return of signed written
consent, led to significant loss of patients after randomization.
Short hospitalizations, significant distances separating multiple
facilities from which we recruited, and a growing trend to care
for VTE patients in the ambulatory setting compelled us to
adapt our approach. Nevertheless, even with improved retention,
we doubt that our intervention would have demonstrated higher-
quality care transition, improved knowledge, or created stronger
beliefs in anticoagulant medication, given the similarities in
socioeconomic status, level of patient activation, or health lit-
eracy across the intervention and control patients of the
completers cohort.
We also acknowledge that we may not have found an effect in
the outcomes we measured because our population consisted of
mostly white patients with high educational attainment and high
patient activation scores. Despite the relatively “advantaged” pop-
ulation we enrolled, the mean scores of the knowledge assessment
were low, arguing for continued efforts to develop interventions to
improve knowledge.
The instrument we used to measure the quality of care transi-
tion, CTM-15, covered medication specific themes but also more
general ones such as confidence in managing one's own health.
The home pharmacist visit and subsequent anticoagulation expert
consultation touched on other themes because they related to
VTE. The relatively long lag between discharge and administra-
tion of the CTM-15 (up to 50 days after randomization) could also
have contributed to the lack of effect, given the difficulty for pa-
tients to recall information provided to them during the homevisit,
which occurred within 1 week of randomization. We attempted to
mitigate this by providing the anticoagulation expert consultation
in the weeks after the home visit, but this seems not to have im-
proved patient ratings.
Another limitation is that our intervention had limited engage-
ment with caregivers and primary care providers. Because we had
not previously tested or validated our simulation exercise to assess
and remediate medication self-management with patient-caregiver
dyads, we decided to assess and remediate proficiency with the
patient alone. We allowed caregivers to be present, but we ac-
knowledge that an intervention that more directly engaged care-
givers may have had more significant impact. Similarly, we
limited our engagement with primary care providers to correspon-
dence sent at the time of discharge informing the provider about
our study. We also did not collect information about whether or
not patients were receiving support from dedicated anticoagula-
tion clinics. Because of loss to follow-up, there may have been re-
sidual confounding from this variable although our treatment
groups were balanced on most covariates. Finally, eight different
pharmacists conducted home visits, and although we provided a
standardized protocol for these visits, we did not have the sample
size available to analyze how variation by pharmacist impacted
our results.
CONCLUSIONS
We executed a multicomponent intervention in patients with
new episodes of VTE. The intervention was feasible in terms of
time, and patients rated the components of the intervention highly.
Nevertheless, we did not detect a significant impact of the inter-
vention on the quality of care transition, patient knowledge, or be-
liefs related to anticoagulants. We welcome additional research to
identify interventions effective at improving these outcomes.
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